Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

IVVD

Invivyd Inc

Feb 06 • 04:00PM ET

1.59

-0.12 -7.02 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX MRK JNJ NVAX AZN-D GSK GILD SNY

| Held by: VTI XBI VXF ITOT PRFZ LABU BBC IBBQ BIB PWS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.47	Insider Own	18.47%	Shs Outstand	277.12M	Perf Week	-8.62%
Market Cap	440.63M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	-0.44%	Shs Float	225.93M	Perf Month	-33.75%
Enterprise Value	358.34M	PEG	-	EPS next Q	-0.08	Inst Own	69.48%	Short Float	9.48%	Perf Quarter	4.61%
Income	-59.86M	P/S	8.81	EPS this Y	72.67%	Inst Trans	23.50%	Short Ratio	3.23	Perf Half Y	110.99%
Sales	50.04M	P/B	3.66	EPS next Y	41.10%	ROA	-39.76%	Short Interest	21.41M	Perf YTD	-35.63%
Book/sh	0.43	P/C	5.19	EPS next 5Y	48.75%	ROE	-67.94%	52W High	3.07 -48.21%	Perf Year	-24.64%
Cash/sh	0.31	P/FCF	-	EPS past 3/5Y	11.20% -24.99%	ROIC	-63.24%	52W Low	0.46 245.65%	Perf 3Y	-29.65%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	86.97%	Volatility	11.13% 8.77%	Perf 5Y	-
Dividend TTM	-	EV/Sales	7.16	EPS Y/Y TTM	75.73%	Oper. Margin	-124.37%	ATR (14)	0.18	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.46	Sales Y/Y TTM	332.71%	Profit Margin	-119.63%	RSI (14)	29.35	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	2.47	EPS Q/Q	87.90%	SMA20	-24.14%	Beta	0.62	Target Price	8.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	41.17%	SMA50	-30.77%	Rel Volume	0.88	Prev Close	1.71
Employees	99	LT Debt/Eq	0.02	Earnings	Nov 06 BMO	SMA200	13.51%	Avg Volume	6.62M	Price	1.59
IPO	Aug 06, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.00% 0.24%	Trades		Volume	5,832,991	Change	-7.02%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-22-25	Initiated	BTIG Research	Buy	$10
Nov-25-25	Downgrade	D. Boral Capital	Buy → Hold
Oct-06-25	Initiated	Cantor Fitzgerald	Overweight	$10
Apr-05-24	Upgrade	Guggenheim	Neutral → Buy	$9
Mar-26-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$4 → $10
Dec-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$1 → $4
May-01-23	Initiated	H.C. Wainwright	Buy	$5

Feb-03-26 07:01AM	Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration (GlobeNewswire) +8.05%
Jan-22-26 07:01AM	Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention (GlobeNewswire)
Jan-20-26 07:01AM	Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 (GlobeNewswire) -8.57%
Jan-14-26 02:13PM	?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 (Insider Monkey) +11.11%
Jan-08-26 07:01AM	Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights (GlobeNewswire)
11:13AM	Loading…
Dec-31-25 11:13AM	BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda (Insider Monkey)
Dec-23-25 07:05AM	Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
07:01AM	Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Dec-22-25 09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly) +25.22%
Dec-18-25 01:14AM	Invivyd, Inc. (IVVD): Advancing RSV Antibody VBY329 Amid Analyst Downgrade (Insider Monkey)
Nov-25-25 07:01AM	Invivyd to Participate at the 8th Annual Evercore Healthcare Conference (GlobeNewswire) -5.42%
Nov-24-25 07:01AM	Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness (GlobeNewswire)
Nov-17-25 10:40PM	Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +20.85% -10.92%
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Nov-06-25 09:15AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Loading…
07:01AM	Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-05-25 07:52AM	Invivyd Inc (IVVD) Q3 2025 Earnings Report Preview: What to Expect (GuruFocus.com) +8.57%
07:40AM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 10:00AM	Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) -13.04%
Nov-03-25 04:01PM	Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025 (GlobeNewswire) -8.52%
Oct-28-25 07:01AM	Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire)
Oct-06-25 07:01AM	Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID (GlobeNewswire) +22.41%
Sep-24-25 04:01PM	Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors (GlobeNewswire) +5.17% -6.56%
Sep-23-25 07:25PM	Invivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody Approval (Insider Monkey)
Sep-17-25 07:01AM	Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer (GlobeNewswire) -8.73%
Sep-04-25 07:01AM	SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 (GlobeNewswire)
Aug-27-25 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire) -15.44%
Aug-26-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +84.03%
Aug-22-25 12:00PM	Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares (GlobeNewswire)
Aug-20-25 11:58PM	Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +11.00% -16.71%
04:01PM	Loading…
04:01PM	Invivyd Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-18-25 04:32PM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ("Stratus") (GlobeNewswire) -17.82%
Aug-14-25 06:00PM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -11.54%
04:49PM	Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
04:47PM	Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 (GlobeNewswire)
Aug-12-25 05:40PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-08-25 05:30AM	The Race to Find a Measles Treatment as Infections Surge (The Wall Street Journal) +5.88%
Aug-07-25 06:15PM	Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.10%
Aug-06-25 08:20AM	Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-23-25 07:01AM	Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire) +5.26%
Jul-21-25 07:05AM	National Comprehensive Cancer Network (NCCN) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population (GlobeNewswire)
Jul-02-25 07:01AM	Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome (GlobeNewswire)
Jun-26-25 07:01AM	Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection (GlobeNewswire) +13.43%
Jun-02-25 03:49AM	COVIDs remaining biotech contenders navigate a dwindling market (Pharma Voice)
May-29-25 02:36PM	H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall (Insider Monkey)
May-27-25 07:01AM	Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus (GlobeNewswire) +20.15%
May-23-25 07:01AM	Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas (GlobeNewswire)
May-21-25 09:30AM	Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 (GlobeNewswire) -5.52%
May-16-25 03:08AM	Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ... (GuruFocus.com) +10.33%
01:57AM	Q1 2025 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-25 08:15AM	Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -15.78%
07:01AM	Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
May-14-25 09:53AM	What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings (GuruFocus.com)
07:01AM	Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy (GlobeNewswire)
May-13-25 07:01AM	Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-12-25 07:01AM	Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles (GlobeNewswire) +29.67%
May-08-25 07:01AM	Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025 (GlobeNewswire)
Apr-21-25 09:58AM	What's Going On With Invivyd Stock On Monday? (Benzinga) +10.00%
07:01AM	Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank (GlobeNewswire)
Mar-26-25 04:15PM	Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors (GlobeNewswire) -6.70%
Mar-20-25 09:25AM	Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:01AM	Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights (GlobeNewswire)
Mar-12-25 09:40AM	Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now? (Zacks)
Mar-05-25 07:05AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 (GlobeNewswire)
Mar-02-25 11:32AM	Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-28-25 12:12PM	Adagio Medical cuts workforce and pauses cryo catheter launch in EU (Medical Device Network) -6.45%
Feb-24-25 07:05AM	FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -29.94%
Feb-18-25 10:27AM	Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far (Insider Monkey) -9.32%
Feb-10-25 07:00AM	Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 (GlobeNewswire) -23.04%
Feb-05-25 09:30AM	Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold (GlobeNewswire) +68.80%
Feb-03-25 07:20PM	Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025 (Insider Monkey) +196.34% +17.92%
07:00AM	Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population (GlobeNewswire)
06:55AM	Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability (GlobeNewswire)
Jan-27-25 07:01AM	Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA's Gating Request for Completing Its Review of EUA Request for PEMGARDA (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients (GlobeNewswire) -12.85%
Jan-10-25 12:12PM	What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday? (Benzinga)
07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variant XEC (GlobeNewswire)
Jan-07-25 09:34AM	Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey)
Dec-17-24 06:25AM	Adagio Medical announces Todd Usen as new CEO and director (Medical Device Network) +8.77%
Nov-15-24 03:17AM	Q3 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
02:11AM	Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ... (GuruFocus.com)
Nov-14-24 08:20AM	Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.18%
07:05AM	Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
07:01AM	Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor (GlobeNewswire)
Nov-13-24 07:27AM	Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com) -11.00%
Nov-12-24 08:30AM	Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively (GlobeNewswire)
Nov-06-24 08:01AM	Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire) +12.62%
07:01AM	Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 (GlobeNewswire)
Oct-29-24 07:03AM	Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability (GlobeNewswire) -12.80%
07:01AM	Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants (GlobeNewswire)
Oct-16-24 07:01AM	Invivyd to Present PEMGARDA (pemivibart) Data at Infectious Disease Week (IDWeek) 2024 (GlobeNewswire)
Oct-01-24 07:01AM	Invivyd Announces U.S. FDA Has Updated the PEMGARDA EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data (GlobeNewswire) -11.75%
Sep-23-24 07:01AM	Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA (pemivibart) (GlobeNewswire)
Sep-12-24 07:01AM	Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 (GlobeNewswire) +12.75%
Sep-05-24 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-04-24 07:01AM	Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA (GlobeNewswire)
Sep-03-24 07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest (GlobeNewswire)
Aug-27-24 07:01AM	Invivyd Announces PEMGARDA (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial (GlobeNewswire) -28.67%
Aug-15-24 02:43AM	Q2 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents) +6.12%
Aug-14-24 09:10AM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.55%
08:01AM	Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADIMAB, LLC	10% Owner	Dec 23 '25	Proposed Sale	3.00	192,320	577,498		Dec 23 04:23 PM
MCLAUGHLIN KEVIN F	Director	Nov 19 '25	Buy	2.50	50,000	125,000	50,000	Nov 20 04:22 PM
ADIMAB, LLC	10% Owner	Nov 17 '25	Proposed Sale	3.00	1,233,416	3,703,455		Nov 17 04:36 PM
Lee Timothy Edward	Chief Commercial Officer	Aug 19 '25	Sale	0.57	29,643	16,796	59,344	Aug 19 09:28 PM
Lee Timothy Edward	Chief Commercial Officer	Aug 18 '25	Sale	0.65	20,013	13,012	88,987	Aug 19 09:28 PM
Duke William E.	Chief Financial Officer	Aug 19 '25	Sale	0.57	29,643	16,796	49,344	Aug 19 09:25 PM
Duke William E.	Chief Financial Officer	Aug 18 '25	Sale	0.65	20,013	13,012	78,987	Aug 19 09:25 PM
Green Julie	Chief Human Resources Officer	Aug 19 '25	Sale	0.57	29,643	16,796	49,344	Aug 19 09:24 PM
Green Julie	Chief Human Resources Officer	Aug 18 '25	Sale	0.65	20,013	13,012	78,987	Aug 19 09:24 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 19 '25	Sale	0.57	49,402	27,991	84,446	Aug 19 09:21 PM
Andersen Jill	Chief Legal Officer, Secretary	Aug 18 '25	Sale	0.65	33,352	21,685	133,848	Aug 19 09:21 PM
Allen Robert D. III	Chief Scientific Officer	Aug 19 '25	Sale	0.57	27,420	15,536	53,068	Aug 19 09:20 PM
Allen Robert D. III	Chief Scientific Officer	Aug 18 '25	Sale	0.65	18,512	12,037	80,488	Aug 19 09:20 PM
Green Julie	Officer	Aug 18 '25	Proposed Sale	0.71	39,600	28,001		Aug 18 06:55 PM
Andersen Jill	Officer	Aug 18 '25	Proposed Sale	0.71	66,000	46,669		Aug 18 06:54 PM
Allen Robert D. III	Officer	Aug 18 '25	Proposed Sale	0.71	36,631	25,902		Aug 18 06:53 PM
Lee Timothy Edward	Officer	Aug 18 '25	Proposed Sale	0.71	39,600	28,001		Aug 18 06:49 PM
Duke William E.	Officer	Aug 18 '25	Proposed Sale	0.71	39,601	28,002		Aug 18 06:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IVVD

Invivyd Inc

Upgrade your FINVIZ experience